Business Description
Telix Pharmaceuticals Ltd
ISIN : AU000000TLX2
Share Class Description:
ASX:TLX: Ordinary SharesCompare
Compare
Traded in other countries / regions
TLX.AustraliaTLPPF.USAT3X.Germany IPO Date
2017-11-15Description
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.37 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 0.3 | |||||
| Interest Coverage | 5.09 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 20.58 | |||||
| Beneish M-Score | -0.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 342.2 | |||||
| 3-Year FCF Growth Rate | 89.8 | |||||
| 3-Year Book Growth Rate | 17.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 199.62 | |||||
| Future 3-5Y Total Revenue Growth Rate | 37.96 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.18 | |||||
| 9-Day RSI | 71.07 | |||||
| 14-Day RSI | 67.94 | |||||
| 6-1 Month Momentum % | 18.18 | |||||
| 12-1 Month Momentum % | 116.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.99 | |||||
| Quick Ratio | 0.87 | |||||
| Cash Ratio | 0.46 | |||||
| Days Inventory | 31.66 | |||||
| Days Sales Outstanding | 41.05 | |||||
| Days Payable | 91.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.9 | |||||
| Shareholder Yield % | -0.15 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.38 | |||||
| Operating Margin % | 12.49 | |||||
| Net Margin % | 7.72 | |||||
| FCF Margin % | 3.34 | |||||
| ROE % | 23.46 | |||||
| ROA % | 10.14 | |||||
| ROIC % | 21.54 | |||||
| ROC (Joel Greenblatt) % | 214.69 | |||||
| ROCE % | 22 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 164.76 | |||||
| Forward PE Ratio | 81.29 | |||||
| PE Ratio without NRI | 164.76 | |||||
| Price-to-Owner-Earnings | 1178.1 | |||||
| PS Ratio | 12.74 | |||||
| PB Ratio | 20.3 | |||||
| Price-to-Tangible-Book | 2455 | |||||
| Price-to-Free-Cash-Flow | 389.68 | |||||
| Price-to-Operating-Cash-Flow | 165.88 | |||||
| EV-to-EBIT | 123.57 | |||||
| EV-to-Forward-EBIT | 43.94 | |||||
| EV-to-EBITDA | 111.3 | |||||
| EV-to-Forward-EBITDA | 41.7 | |||||
| EV-to-Revenue | 12.75 | |||||
| EV-to-Forward-Revenue | 6.15 | |||||
| EV-to-FCF | 384.15 | |||||
| Price-to-Graham-Number | 116.9 | |||||
| Earnings Yield (Greenblatt) % | 0.81 | |||||
| FCF Yield % | 0.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Telix Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 637.078 | ||
| EPS (TTM) (A$) | 0.149 | ||
| Beta | 1.62 | ||
| Volatility % | 27.44 | ||
| 14-Day RSI | 67.94 | ||
| 14-Day ATR (A$) | 0.771832 | ||
| 20-Day SMA (A$) | 23.1525 | ||
| 12-1 Month Momentum % | 116.45 | ||
| 52-Week Range (A$) | 9.06 - 24.91 | ||
| Shares Outstanding (Mil) | 334.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Telix Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Telix Pharmaceuticals Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Telix Pharmaceuticals Ltd Frequently Asked Questions
What is Telix Pharmaceuticals Ltd(ASX:TLX)'s stock price today?
The current price of ASX:TLX is A$24.55. The 52 week high of ASX:TLX is A$24.91 and 52 week low is A$9.06.
When is next earnings date of Telix Pharmaceuticals Ltd(ASX:TLX)?
The next earnings date of Telix Pharmaceuticals Ltd(ASX:TLX) is 2025-02-21 Est..
Does Telix Pharmaceuticals Ltd(ASX:TLX) pay dividends? If so, how much?
Telix Pharmaceuticals Ltd(ASX:TLX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers